Talis Biomedical Corporation

TLIS Healthcare Medical Devices

Talis Biomedical Corporation’s revenue for fiscal 2023 (year ended December 2023) was $2.1 million, down 55.7% from fiscal 2022. Operating cash flow growth for three consecutive years.

2.84 0.00 0.00%
Market cap
$46.3M
P/E
0.0×
Fwd P/E
−0.3×
Dividend yield
—
F-score
4/9
Altman Z
−9.10
Beneish M
−4.89
Dividend safety
n/a
Jun '24 Mar '24 Dec '23 Sep '23 Older periods
Piotroski F-Score
— 4 4 3

+8 more TTM periods

ROE
(70.48%) (68.60%) (63.32%) (64.53%)
ROA
(52.13%) (53.08%) (46.98%) (50.10%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(91.40%) (90.34%) (86.19%) (89.41%)
Average Days of Receivables
— 2.21 8.55 0.83
Free Cash Flow per Share
(22.02) (23.95) (29.56) (30.81)
Free Cash Flow
(40.12) (43.63) (53.73) (56.05)
Other line items

Show all line items

Columns are period end dates